With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen

FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections. The post With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen appeared…

Read More

4 Execs’ Wishes for a Better Healthcare Future

At DiMe’s Healthcare 2030 Summit, four healthcare leaders shared the innovations they believe could most improve care, from AI-driven solutions to reduce medical errors to stronger primary care relationships that could save billions. The post 4 Execs’ Wishes for a Better Healthcare Future appeared first on MedCity News.

Read More

4 Execs’ Wishes for a Better Healthcare Future

At DiMe’s Healthcare 2030 Summit, four healthcare leaders shared the innovations they believe could most improve care, from AI-driven solutions to reduce medical errors to stronger primary care relationships that could save billions. The post 4 Execs’ Wishes for a Better Healthcare Future appeared first on MedCity News.

Read More

Private Equity in the Hospital Industry

That is the title of a recent paper by Gao, Kim, and Sevilir (2025). The authors examine 1218 hospital merger and acquisition (M&A) deals in the hospital industry between 2001 and 2008. The authors focus solely on M&A deals with for-profit entities as they argue that they want to examine whether private equity (PE) specifically…

Read More